Please assess the completion status of the following clinical trial:

Trial Title: Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)~* Post-bronchodilator forced expiratory volume at one second~  /forced vital capacity (FEV1/FVC) level less than 70%~* Ten or more pack-years of smoking~* Willing to make return visits to the study clinic and accept telephone contact~* Last pneumococcal vaccination occured at least 5 years prior to study entry~Exclusion Criteria:~* Asthma~* Sensitivity to pneumococcal vaccine~* Known bleeding disorder, or requires long-term anticoagulation therapy~* Presence of chronic disease that may impair pneumococcal vaccine response~* Acute illness requiring antibiotics in the month prior to study entry~* Medical condition that makes survival for 24 months following study entry unlikely~* Pregnant

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pneumovax (PPSV23) (Type: ACTIVE_COMPARATOR): pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)
- Prevnar (PCV7) (Type: ACTIVE_COMPARATOR): diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose

Based on this trial design, predict the completion outcome and termination type (if applicable).